Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies
- Author
- FRAZER, Alan1
[1] Department of Pharmacology, University of Texas Health Science Center at San Antonio, and Audie L. Murphy Memorial Hospital, South Texas Veterans Health Care System, San Antonio, United States - Conference title
- Remission of anxiety-related disorders
- Conference name
- Symposium Remission of Anxiety-Related Disorders (Washington, D.C. 2000-10-06)
- Source
The Journal of clinical psychiatry. Supplement. 2001, Vol 62, Num 12, pp 16-23 ; ref : 53 ref
- Scientific domain
- Psychology, psychopathology, psychiatry
- Publisher
- Physicians Postgraduate Press, Memphis, TN
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Animal Antidépresseur Article synthèse Chimiothérapie Composé tricyclique Efficacité biologique relative Efficacité traitement Encéphale Etat dépressif Etude comparative Homme In vitro Inhibiteur recapture Liquide céphalorachidien Mécanisme action Noradrénaline Prédiction Rat Système nerveux central Sérotonine Traitement Trouble anxieux Mammalia Psychotrope Rodentia Sélectivité Tranquillisant Trouble humeur Vertebrata
- Keyword (en)
- Animal Antidepressant agent Review Chemotherapy Tricyclic compound Relative biological effectiveness Treatment efficiency Brain (vertebrata) Depression Comparative study Human In vitro Reuptake inhibitor Cerebrospinal fluid Mechanism of action Norepinephrine Prediction Rat Central nervous system Serotonin Treatment Anxiety disorder Mammalia Psychotropic Rodentia Selectivity Tranquillizer Mood disorder Vertebrata
- Keyword (es)
- Animal Antidepresor Artículo síntesis Quimioterapia Compuesto tricíclico Eficacia biológica relativa Eficacia tratamiento Encéfalo Estado depresivo Estudio comparativo Hombre In vitro Inhibidor recaptura Líquido cefalorraquídeo Mecanismo acción Noradrenalina Predicción Rata Sistema nervioso central Serotonina Tratamiento Trastorno ansiedad Mammalia Psicotropo Rodentia Selectividad Tranquilizante Trastorno humor Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B02 Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B03 Psycholeptics: tranquillizer, neuroleptic.
- Discipline
- Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 1142967
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:9:\"\u0000*\u0000jtitle\";s:46:\"The Journal of clinical psychiatry. Supplement\";s:9:\"\u0000*\u0000stitle\";s:0:\"\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:2:\"16\";s:8:\"\u0000*\u0000epage\";s:2:\"23\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:0:\"\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"FRAZER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Alan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:38:\"Remission of anxiety-related disorders\";s:8:\"\u0000*\u0000title\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:8:\"\u0000*\u0000place\";s:11:\"Memphis, TN\";s:6:\"\u0000*\u0000pub\";s:29:\"Physicians Postgraduate Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:9:\"\u0000*\u0000jtitle\";s:46:\"The Journal of clinical psychiatry. Supplement\";s:9:\"\u0000*\u0000stitle\";s:0:\"\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:2:\"16\";s:8:\"\u0000*\u0000epage\";s:2:\"23\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:0:\"\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"FRAZER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Alan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:38:\"Remission of anxiety-related disorders\";s:8:\"\u0000*\u0000title\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:8:\"\u0000*\u0000place\";s:11:\"Memphis, TN\";s:6:\"\u0000*\u0000pub\";s:29:\"Physicians Postgraduate Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:9:\"\u0000*\u0000jtitle\";s:46:\"The Journal of clinical psychiatry. Supplement\";s:9:\"\u0000*\u0000stitle\";s:0:\"\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:2:\"16\";s:8:\"\u0000*\u0000epage\";s:2:\"23\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:0:\"\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"FRAZER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Alan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:38:\"Remission of anxiety-related disorders\";s:8:\"\u0000*\u0000title\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:8:\"\u0000*\u0000place\";s:11:\"Memphis, TN\";s:6:\"\u0000*\u0000pub\";s:29:\"Physicians Postgraduate Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:9:\"\u0000*\u0000jtitle\";s:46:\"The Journal of clinical psychiatry. Supplement\";s:9:\"\u0000*\u0000stitle\";s:0:\"\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:2:\"16\";s:8:\"\u0000*\u0000epage\";s:2:\"23\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:0:\"\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"FRAZER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Alan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:38:\"Remission of anxiety-related disorders\";s:8:\"\u0000*\u0000title\";s:106:\"Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies\";s:8:\"\u0000*\u0000place\";s:11:\"Memphis, TN\";s:6:\"\u0000*\u0000pub\";s:29:\"Physicians Postgraduate Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
